Phase I/II – Other

643 trials 280 recruiting

Filter these 643 trials by condition, country, sponsor and more.

Open in Search →

EXLIBRIS : “EXL-01 combined with nivolumab for advanced NSCLC refractory to immunotherapy” Recruiting

2023-505285-28-01 Patients (male or female) ≥18 years old with histologic 2024-07-16
Dose Escalation and Dose Expansion Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Patients with Advanced … Recruiting

2023-508178-27-00 Participants with Advanced KRASG12C-Mutated Solid Tumor 2024-07-10
OSAGE : Phase I-II study chemoradiation in elderly patients with oesophagus cancer Recruiting

2024-514998-21-00 cancer de l'oesophage 2024-07-10
Phase I/II, open-label, multi-center study to evaluate the safety and efficacy of glyco-humanized polyclonal antibody directed against tumor… Recruiting

2023-509648-88-00 Peripheral T cells lymphoma (PTCL) 2024-07-09
Pan-lesions SBRT combined with lymphocyte support through ATRA-driven blockade of MDSC in patients with oligometastatic solid cancer (LySATR… Recruiting

2022-500680-13-00 Oligometastatic solid cancer 2024-07-04
TRAUMACELL - Effects of intravascular administration of mesenchymal stromal cells derived from Wharton’s Jelly of the umbilical cord on syst… Recruiting

2023-504415-33-00 Patients aged 15 years and 3 months and older with seve 2024-06-25
INJECTABL-II trial: Dose finding, efficacy and immunological response of a novel immuno-adjuvant (IP-001) following microwave ablation or ir… Recruiting

2023-504572-25-00 Colorectal liver metastases 2024-06-25
Dose-finding for dobutamine during transitional circulation in the very preterm infant Recruiting

2023-504915-34-00 Neonates with haemodynamic insufficiency 2024-06-20
Choice Of the Most Active Strategies for Short term recurring Triple Negative Breast Cancer A phase Ib/II, open-label, modular, dose-finding… Recruiting

2023-503606-36-00 Patients with hormone-receptor negative and HER2-negati 2024-06-17
A clinical trial applying Regulatory T cells in kidney transplant recipients to investigate the safety and tolerability as an adjunctive the… Recruiting

2024-514398-23-00 Solid organ transplantation (Kidney) 2024-06-10
Multicentric trial on the use of combined therapy of Thiamine and biotine in patients with Huntington´s disease. Recruiting

2023-508637-14-00 Huntington´s disease. 2024-06-06
Safety and diagnostic performance of uPAR PET imaging in localised, untreated prostate cancer. Recruiting

2023-507111-35-00 Prostate Cancer 2024-06-03
A Phase 1b/2 Study of BGB-11417 as Monotherapy and in Various Combinations with Dexamethasone plus Carfilzomib, Dexamethasone plus Daratumum… Recruiting

2023-507751-30-00 relapsed or refractory multiple myeloma 2024-05-27
COMBINATORY IMMUNOTHERAPY-2 (COM-IT-2) A phase 2 randomised open two-arm study to assess the tolerability and efficacy of immunotherapy comb… Recruiting

2023-510089-28-00 Non-small cell lung cancer (Stage IV) 2024-05-22
A phase 1/2 multicenter open-label study to investigate treatment of hydroxyurea (HU) in combination with valproic acid (VPA) or 6- mercapto… Recruiting

2022-501992-15-00 Acute Myeloid Leukemia (AML) 2024-05-21
A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants with Chronic Mye… Recruiting

2023-507677-18-00 Chronic Myeloid Leukemia 2024-05-17
Long-Term Follow-Up of Subjects Treated With NTLA-2002 Recruiting

2023-507956-56-00 Hereditary Angioedema 2024-05-17
Long-Term Follow-up of Patients Treated with Miltenyi Cell and Gene Therapies Recruiting

2022-501648-14-00 Relapsed or refractory CD19 positive B cell malignancie 2024-05-05
Mesenchymal stromal cells treatment in Lyell syndrome: A pilot phase 1-2 open trial (LYSYME) Recruiting

2024-516404-42-00 Adults diagnosed with SJS-TEN with at least 10% of body 2024-04-15
HOVON 165 CLL: A prospective randomized phase I/II trial of venetoclax treatment (26 cycles) with 6 cycles or 12 cycles of epcoritamab in pa… Recruiting

2022-500305-40-00 Chronic Lymphocytic Leukemia 2024-04-10
Evaluation of EXL01 a new Live Biotherapeutic Product to prevent recurrence of Clostridioides difficile infection in high-risk patients. LIV… Recruiting

2023-506232-32-00 Multiple recurrences of Clostridioides difficile infect 2024-04-08
An Open-Label Exploratory Study of Fosigotifator in Subjects with Vanishing White Matter Disease Recruiting

2023-505704-30-00 Vanishing White Matter disease 2024-03-22
A Modular Open-Label, Multi-Centre Phase 1/2 Dose-Finding, Optimisation, and Expansion Study to Evaluate the Safety,Tolerability, Pharmacoki… Recruiting

2023-507738-26-00 Breast Cancer 2024-03-20
Safety and feasibility of immuno-OCT Recruiting

2023-506395-27-00 Barrett's esophagus 2024-03-15